Welcome to our dedicated page for Rockwell Medical (DE) news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Medical (DE) stock.
Rockwell Medical, Inc. (DE), trading under the symbol RMTI, is a leading biopharmaceutical company dedicated to addressing the needs of patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company has positioned itself at the forefront of renal care through its innovative products and services focusing on iron replacement, secondary hyperparathyroidism, and hemodialysis.
One of Rockwell Medical's groundbreaking therapies is Triferic, the first and only FDA-approved drug designed to replace iron and maintain hemoglobin levels in hemodialysis patients with anemia. Triferic works during each dialysis session by replacing the 5-7 mg iron loss that is typical in all patients, thereby maintaining their iron balance. Differing from traditional intravenous (IV) iron products, Triferic binds immediately to transferrin (the body's iron carrier) and is swiftly transported to the bone marrow for incorporation into hemoglobin. This unique mechanism ensures no increase in ferritin (stored iron and inflammation) and eliminates the risks of anaphylaxis, addressing a critical unmet need for functional iron deficiency (FID) in ESRD patients.
Rockwell Medical is also a prominent supplier of dialysis concentrates in the United States. Their diverse product portfolio includes notable brands such as CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate. These products are essential for dialysis providers, helping to ensure that patients receive the necessary treatments for effective dialysis.
The company's commitment to innovation and quality is reflected in its ongoing projects and recent achievements. Rockwell Medical continues to focus on expanding its product line and enhancing its manufacturing processes to meet the evolving needs of the renal care market. Financially, the company maintains a robust position with strategic partnerships and collaborations that further bolster its market presence and capabilities.
For those interested in the latest updates and developments regarding Rockwell Medical, Inc., the company's news section provides current information on performance, events, and significant milestones.
Rockwell Medical, Inc. (Nasdaq: RMTI) will release its financial and operational results for Q1 2023 on May 15, 2023, at 6:00 am ET. Following the release, a live conference call and webcast will take place at 8:00 am ET. The call will discuss the company’s performance and include a Q&A session with executives, including Mark Strobeck, Ph.D., President and CEO, and Paul McGarry, CPA, SVP, Finance.
Rockwell Medical focuses on developing, manufacturing, and distributing hemodialysis products, serving as the second largest supplier of acid and bicarbonate concentrates in the U.S. The company aims to become the global leader in hemodialysis concentrates, highlighting its long-term growth strategies and commitment to quality and customer service.
Rockwell Medical, Inc. (Nasdaq: RMTI) is showcasing its hemodialysis concentrates portfolio at the National Kidney Foundation Spring Clinical Meetings from April 11-15, 2023, in Austin, Texas. The portfolio features products such as CitraPure®, Dri-Sate®, RenalPure®, and SteriLyte®, designed to improve treatment efficiency and reduce costs for dialysis providers. Rockwell is the second-largest supplier of acid and bicarbonate concentrates in the U.S., aiming to be the leading global supplier. The company focuses on delivering high-quality products and exceptional customer service to enhance the lives of patients with end-stage kidney disease. Rockwell Medical is recognized as a Great Place to Work® in 2023.
Rockwell Medical, a healthcare company focused on hemodialysis products, reported a 26.0% increase in fourth-quarter revenue, reaching $19.3 million, and an annual revenue of $72.8 million in 2022, up 17.6% year-over-year. The company significantly reduced its debt from $21.6 million to $10.0 million and lowered operational cash usage to $594,000 from $9.0 million in Q4 2021. Despite a net loss of $2.4 million for Q4 and $18.7 million for the full year, Rockwell aims for profitability with 2023 guidance projecting sales between $78.0 million and $82.0 million.
Rockwell Medical (Nasdaq: RMTI) will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion40 (DTX40) from March 28-31, 2023, in Las Vegas, Nevada. The Company is exhibiting at Booth #502, featuring products like CitraPure® Citric Acid Concentrate and Dri-Sate® Dry Acid Concentrate. Rockwell Medical is recognized as the second-largest supplier of acid and bicarbonate concentrates for dialysis in the U.S. The Company aims to enhance its offerings and provide quality service to dialysis providers while striving to become the leading global supplier of hemodialysis concentrates.
Rockwell Medical (Nasdaq: RMTI) has achieved Great Place to Work Certification™ in 2023 during its first year of participation. This recognition is based solely on employee feedback regarding workplace experiences, emphasizing high-trust environments. The certification reflects Rockwell’s commitment to providing quality products and exceptional customer service for dialysis clinics and patients. With a mission to enhance hemodialysis care, Rockwell is the second-largest supplier of dialysis concentrates in the U.S. and aims to become a global leader in this sector.
Rockwell Medical, Inc. (Nasdaq: RMTI) announced it will release its financial and operational results for Q4 and the full year ending December 31, 2022, on March 30, 2023, at 6:00 AM ET. A live conference call will follow at 8:00 AM ET, where management will discuss the results, including operational performance and future outlook. Rockwell Medical is recognized as the second largest supplier of hemodialysis products in the U.S., focusing on improving patient care through innovative healthcare solutions.
Rockwell Medical, Inc. (Nasdaq: RMTI) has signed a three-year product purchase agreement with Concerto Renal Services, the largest provider of dialysis in skilled nursing facilities in the U.S. The agreement positions Rockwell as the primary supplier of hemodialysis concentrates, contributing millions in annual revenue. The U.S. hemodialysis concentrates market is valued at $380 million, projected to grow to $500 million by 2026, driven by an increase in end-stage kidney disease patients. Rockwell aims for profitability in 2024, emphasizing its commitment to becoming a global leader in the sector.
Rockwell Medical (RMTI) has secured a multi-million dollar, three-year product purchase agreement with the largest non-profit dialysis provider in the U.S. This agreement positions Rockwell as the preferred supplier of liquid and dry acid and bicarbonate concentrates to hemodialysis facilities nationwide. CEO Mark Strobeck expressed enthusiasm, emphasizing this deal as a foundation for revenue growth and profitability by 2024. The hemodialysis concentrates market is valued at $380 million, with projections reaching $500 million by 2026 due to rising end-stage kidney disease cases. Rockwell is the second largest supplier in this vital market.
Rockwell Medical (NASDAQ: RMTI) has expanded its business into Minnesota, supplying hemodialysis concentrates to clinics there since December 5, 2022. The company anticipates onboarding all clinics by January 1, 2023, expecting over $1 million in revenue in the first year. As the second-largest U.S. supplier of these products, Rockwell is well-positioned in a market expected to grow from $380 million to $500 million by 2026 due to increasing end-stage kidney disease cases. The company aims for annual revenue of $100 million in the coming years.
Rockwell Medical, Inc. (RMTI) is restructuring to capitalize on the hemodialysis market, aiming for profitability in 2024. The company reduced long-term debt from $15 million to $10 million and achieved a record quarterly revenue of $18.7 million for Q3 2022, marking a 16.9% year-over-year increase. Cash used in operations fell by 81% to $1.1 million. Rockwell is reacquiring distribution rights for its hemodialysis concentrates and expects annual revenue could reach $100 million soon. Despite challenges, the company maintains high demand for its products.
FAQ
What is the current stock price of Rockwell Medical (DE) (RMTI)?
What is the market cap of Rockwell Medical (DE) (RMTI)?
What does Rockwell Medical, Inc. specialize in?
What is Triferic?
How does Triferic differ from traditional IV iron products?
What types of dialysis concentrates does Rockwell Medical offer?
Where is Rockwell Medical's market focus?
What recent achievements has Rockwell Medical made?
What unmet need does Triferic address?
How can I stay updated on Rockwell Medical's latest news?
What is Rockwell Medical's financial condition?
How does Rockwell Medical maintain its market relevance?
